

REMARKS

Claims 11-14 have been amended. No claims are canceled by the present amendment. Upon entry of the amendment, claims 11-26 will be pending for the Examiner's consideration.

Applicants respectfully request reconsideration and withdrawal of the outstanding objections and rejections, in light of the foregoing amendments and following remarks.

Support for the amendments to claims 11-14 can be found in the specification at, for example, page 5 lines 25-30, page 7 lines 1-11 and page 17 lines 9-15 inclusive.

No new matter is added by the amendments to the claims.

Rejection under 35 U.S.C. § 112, first paragraph

Claims 11-26 were rejected under 35 U.S.C. § 112, first paragraph, for the reasons set forth on pages 2-5 of the Office Action. The Applicants submit that the specification provides *in vitro* data to support the amended claims, and provides ample enabling support for *c-kit* kinase mediated conditions. By the present amendments, Applicants believe the rejection has been overcome, and respectfully request that the rejection be withdrawn.

Conclusion

Applicants submit that the application is in condition for allowance. Early Notice of Allowance is respectfully requested. Should there be any issues that have not been addressed to the Examiners satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: 04/28/2005



Vincent P. Liptak
Agent For Applicants
Registration No. 53,225

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7908
Fax: (858) 678-8233